Brief: CSL And Lilly Enter Licensing Agreement For Clazakizumab
17/02/2026 21:19
Feb 18 (Reuters) - CSL Ltd CSL.AX: CSL AND LILLY ENTER LICENSING AGREEMENT FOR CLAZAKIZUMAB EXCLUSIVE LICENSING AGREEMENT GRANTING CERTAIN RIGHTS TO DEVELOP AND COMMERCIALISE CLAZAKIZUMAB CSL WILL RECEIVE AN UPFRONT PAYMENT OF $100 MILLION CSL WILL RETAIN EXCLUSIVE RIGHTS TO DEVELOP AND COMMERCIALISE CLAZAKIZUMAB FOR PREVENTION OF CARDIOVASCULAR EVENTS IN PATIENTS WITH END-STAGE KIDNEY DISEASE Further company coverage: CSL.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Csl
See all newsEU Commission opens antitrust probe into Sanofi's flu vaccine campaign (updated)
EU Commission opens antitrust probe into Sanofi's flu vaccine campaign
Analysis: US prices for new drugs fell in 2025 as fewer costly gene therapies were launched
US military requires flu vaccine for some after outbreak in Texas training center
Corrected: BUZZ-Australian healthcare stocks hit a six-week high, acting as a primary hedge on ASX